NDC product
XOPENEX HFA
NDC 27437-056 · Lupin Pharmaceuticals, Inc.
Key facts
| Product NDC | 27437-056 |
|---|---|
| Proprietary name | XOPENEX HFA |
| Nonproprietary name | levalbuterol tartrate |
| Substances | LEVALBUTEROL TARTRATE |
| Dosage form | AEROSOL, METERED |
| Route | ORAL |
| Labeler | Lupin Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA021730 |
| Pharmacologic classes | Adrenergic beta2-Agonists [MoA], beta2-Adrenergic Agonist [EPC] |
| Marketing start | Nov 10, 2023 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: